Medical/Pharmaceuticals
ISCT 2023: Late-breaking SCG101 Data Show 100% HBsAg+ Hepatocyte Eradication and 74.5% HCC Tumour Reduction With Single Dose HBsAg-specific TCR-T Cell Therapy
SINGAPORE, June 5, 2023 /PRNewswire/ -- SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company developing novel immunotherapies for infectious diseases and their associated cancers, presented late-breaking data from its first-in-class autologous HBsAg-specific T-Cell receptor-engi...
2023-06-05 10:28
2629
Harbour BioMed Announces First Patient Dosed in Phase I Study of First-in-Class Anti-B7H7 (HHLA2) Antibody HBM1020
* HBM1020 is a first-in-class therapeutic monoclonal antibody against B7H7/HHLA2 entering clinical development globally. * HBM1020 was generated from Harbour Mice® H2L2 transgenic mice platform. * HBM1020 has great potential to address huge unmet medical needs in patients with advanced malig...
2023-06-05 09:01
2118
LOTTE BIOLOGICS to Kick off their CDMO Business Campaign at 'BIO International Convention 2023'
* Exclusive booth and private meeting rooms to be utilized for robust business initiatives SEOUL, South Korea, June 4, 2023 /PRNewswire/ -- LOTTE BIOLOGICS, under the leadership of CEORichard Lee, enthusiastically disclosed its participation in the upcoming 'BIO International Convention 2023' t...
2023-06-05 08:27
2247
VVN539 met primary study endpoints in US phase IIa clinical study for the treatment of glaucoma
SHANGHAI, June 4, 2023 /PRNewswire/ -- This was a Phase 2, double-masked, randomized, vehicle-controlled, dose-response study to assess the safety and ocular hypotensive efficacy of VVN539 in subjects with primary open angle glaucoma (POAG) or ocular hypertension (OHT). The primary objective was ...
2023-06-05 08:00
2133
Innovent Presents Phase 1b Clinical Data of IBI110 (Anti-LAG-3 Monoclonal Antibody) at the 2023 ASCO Annual Meeting
ROCKVILLE, Md. and SUZHOU, China, June 5, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and...
2023-06-05 08:00
5043
Turn Biotechnologies Founder to be Featured Speaker at Japanese Society of Anti-Aging Medicine Meeting
MOUNTAIN VIEW, Calif., June 5, 2023 /PRNewswire/ -- Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines for untreatable, age-related conditions, announced that its co-founderVittorio Sebastiano will be a featured participant at one of the world's longest-running conf...
2023-06-05 08:00
2369
Innovent Updates Phase 1b Data of IBI939 (Anti-TIGIT Monoclonal Antibody) Combined with Sintilimab in Previously Untreated PD-L1-selected NSCLC at the 2023 ASCO Annual Meeting
ROCKVILLE, Md. and SUZHOU, China, June 4, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and...
2023-06-04 08:36
4388
Gracell Biotechnologies Presents Updated Data of Deep and Durable Responses for FasTCAR-T GC012F in Relapsed/Refractory Multiple Myeloma at 2023 ASCO Annual Meeting
Data on BCMA/CD19 dual-targeting FasTCAR-T GC012F showed 100% minimal residual disease (MRD) negativity and 82.8% MRD negative stringent complete response (sCR) in a predominantly high-risk relapsed/refractory multiple myeloma (RRMM) population Data on GC012F for treatment of B-NHL will be prese...
2023-06-04 02:15
3508
Sanyou launches new European offices and continues to promote global business landscape
SHANGHAI, June 3, 2023 /PRNewswire/ -- In May 2023, following the CIC Boston branch in US, Sanyou opens new offices in The Shard London and CIC Rotterdam respectively, to rapidly promote the globalization of business landscape. Headquartered in Shanghai China, Sanyou Biopharmaceuticals Co., Ltd. ...
2023-06-03 20:05
3511
Innovent Announces the Second Breakthrough Therapy Designation by NMPA for Olverembatinib for the Treatment of Patients with SDH-Deficient GIST
ROCKVILLE, Md. and SUZHOU, China, June 3, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and...
2023-06-03 07:59
22553
Anti- Ageing and Reproductive Medical Giants to Gather in Hong Kong, Dragon's Medical Leads Chinese Medical Development
Hong Kong, June 2, 2023 /PRNewswire/ -- Dragon's Medical
2023-06-02 23:02
5523
United Imaging to Unveil Ultra-Modern MRI Technology Platform at ISMRM in Toronto
In addition to the uMR® Jupiter 5T, the 12-year old company will exhibit its uAIFi artificial intelligence technology platform and translational medical research systems, and present an open MR development platform that includes AI-empowered reconstruction. HOUSTON, June 2, 2023 /PRNewswire/ -- ...
2023-06-02 22:00
4462
Trajan's Microsampling Devices Meet IVDR Compliance in Europe, UK
Mitra® and hemaPEN® receive regulatory certification as medical devices for remote blood sample collection in healthcare, clinical trials and home monitoring programs inEurope and United Kingdom. MELBOURNE, Australia, June 2, 2023 /PRNewswire/ -- Trajan Scientific and Medical, a leading provider...
2023-06-02 20:00
2858
Transcenta Holding Limited (6628.HK) to Hold 2023 ASCO Business Update call Conference.
SUZHOU, China, June 2, 2023 /PRNewswire/ -- The management team of Transcenta Holding Limited (06628.HK) will attend the 2023 ASCO Business Update Call conference onJune 7, 2023. Transcenta is a clinical stage biopharmaceutical company with fully integrated capabilities in the discovery, research...
2023-06-02 19:14
5232
Latest Updates of 9 Viva's Portfolio Companies
HONG KONG, June 2, 2023 /PRNewswire/ -- Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies' long-term development. This continuous innovation keeps companies up to date and promotes the evolution of R&D and the succ...
2023-06-02 18:51
3494
Invivoscribe Partners with Complete Genomics to Develop and Commercialize Biomarker Tests for Oncology and Cancer Research
SAN DIEGO and SAN JOSE, Calif., June 2, 2023 /PRNewswire/ -- Invivoscribe and Complete Genomics announced today that they had entered a partnership to develop and commercialize biomarker tests on Complete Genomics' NGS platforms. The territory is worldwide, and the field is oncology and cancer...
2023-06-02 18:00
3506
TWi Biotechnology Exploring Promising Treatment for Granuloma Annulare (GA)
Company and Yale University Hospital seeking participants with GA for Phase 1 trials of medicine FDA-approved for other ailments NEW HAVEN, Conn., June 2, 2023 /PRNewswire/ -- TWi Biotechnology (TWiB), a clinical stage biopharmaceutical company specializing in development of repositioned drugs f...
2023-06-02 15:51
2019
Sunway Medical Centre Velocity Awarded by Frost & Sullivan for Leading the Malaysian Hospital Industry with Holistic Medical Care and Pioneering Technologies
Sunway Medical Centre Velocity in Kuala Lumpur delivers a wide range of medical specialties supported by highly trained professionals and advanced technologies. SAN ANTONIO, June 2, 2023 /PRNewswire/ -- Frost & Sullivan recently researched the Malaysian hospital industry and, based on its finding...
2023-06-02 11:46
2895
NMPA accepted Akeso's ebronucimab (PCSK9) marketing application in two cardiovascular indications
HONG KONG, June 1, 2023 /PRNewswire/ -- Akeso Inc. (9926. HK, "Akeso") announced today thatChina's National Medical Products Administration (NMPA) has accepted its New Drug Application (NDA) for its fully human anti-PCSK9 monoclonal antibody ebronucimab (AK102) for 2 indications 1) primary hyper...
2023-06-02 11:43
2181
GC Biopharma receives a business license for the construction of a plasma fractionation plant and technology transfer in Indonesia
* In recognition of securing high-caliber technology in manufacturing plasma derivatives and a track record of overseas plasma fractionation plant construction and technology transfer YONGIN, South Korea, June 1, 2023 /PRNewswire/ -- GC Biopharma, a South Korean biopharmaceutical company, anno...
2023-06-02 08:35
2308
Week's Top Stories
Most Reposted
Agoda releases generative AI film to capture the joy of travel
[Picked up by 349 media titles]
2024-12-10 10:00
Mastercard Economics Institute: APAC growth expected to hold steady in 2025; global policy resets may see shift in gears
[Picked up by 313 media titles]
2024-12-10 09:00Building Asia's Future: Omni HR Secures $7.4mn for HR Tech Expansion
[Picked up by 306 media titles]
2024-12-09 10:00
CCTV+: Yuhang Journey ǀ Follow Olivier to Explore Ancient Liangzhu and Savor Jingshan Tea
[Picked up by 283 media titles]
2024-12-08 20:076th HIIFF Closes with Golden Coconut Award Ceremony
[Picked up by 282 media titles]
2024-12-11 22:19
Most Read
Agoda releases generative AI film to capture the joy of travel
2024-12-10 10:00
3700
Blokees' Figures from Multiple IPs Amaze Fans at 2024 Singapore Comic Con
2024-12-08 00:23
3560
Building Asia's Future: Omni HR Secures $7.4mn for HR Tech Expansion
2024-12-09 10:00
3476